153 related articles for article (PubMed ID: 29560112)
1. Systematic identification of functionally relevant risk alleles to stratify aggressive versus indolent prostate cancer.
Nowinski S; Santaolalla A; O'Leary B; Loda M; Mirchandani A; Emberton M; Van Hemelrijck M; Grigoriadis A
Oncotarget; 2018 Feb; 9(16):12812-12824. PubMed ID: 29560112
[TBL] [Abstract][Full Text] [Related]
2. Molecular model for neuroendocrine prostate cancer progression.
Chen R; Dong X; Gleave M
BJU Int; 2018 Oct; 122(4):560-570. PubMed ID: 29569310
[TBL] [Abstract][Full Text] [Related]
3. Profiling Prostate Cancer Therapeutic Resistance.
Wade CA; Kyprianou N
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562686
[TBL] [Abstract][Full Text] [Related]
4. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
[TBL] [Abstract][Full Text] [Related]
5. Local treatment for metastatic prostate cancer: A systematic review.
Tilki D; Pompe RS; Bandini M; Marchioni M; Kretschmer A; Tian Z; Karakiewicz PI; Evans CP
Int J Urol; 2018 May; 25(5):390-403. PubMed ID: 29572963
[TBL] [Abstract][Full Text] [Related]
6. Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.
Wedge DC; Gundem G; Mitchell T; Woodcock DJ; Martincorena I; Ghori M; Zamora J; Butler A; Whitaker H; Kote-Jarai Z; Alexandrov LB; Van Loo P; Massie CE; Dentro S; Warren AY; Verrill C; Berney DM; Dennis N; Merson S; Hawkins S; Howat W; Lu YJ; Lambert A; Kay J; Kremeyer B; Karaszi K; Luxton H; Camacho N; Marsden L; Edwards S; Matthews L; Bo V; Leongamornlert D; McLaren S; Ng A; Yu Y; Zhang H; Dadaev T; Thomas S; Easton DF; Ahmed M; Bancroft E; Fisher C; Livni N; Nicol D; Tavaré S; Gill P; Greenman C; Khoo V; Van As N; Kumar P; Ogden C; Cahill D; Thompson A; Mayer E; Rowe E; Dudderidge T; Gnanapragasam V; Shah NC; Raine K; Jones D; Menzies A; Stebbings L; Teague J; Hazell S; Corbishley C; ; de Bono J; Attard G; Isaacs W; Visakorpi T; Fraser M; Boutros PC; Bristow RG; Workman P; Sander C; ; Hamdy FC; Futreal A; McDermott U; Al-Lazikani B; Lynch AG; Bova GS; Foster CS; Brewer DS; Neal DE; Cooper CS; Eeles RA
Nat Genet; 2018 May; 50(5):682-692. PubMed ID: 29662167
[TBL] [Abstract][Full Text] [Related]
7. Shifting the Paradigm of Testosterone Replacement Therapy in Prostate Cancer.
Bell MA; Campbell JD; Joice G; Sopko NA; Burnett AL
World J Mens Health; 2018 May; 36(2):103-109. PubMed ID: 29623698
[TBL] [Abstract][Full Text] [Related]
8. Factors Influencing Men's Choice of and Adherence to Active Surveillance for Low-risk Prostate Cancer: A Mixed-method Systematic Review.
Kinsella N; Stattin P; Cahill D; Brown C; Bill-Axelson A; Bratt O; Carlsson S; Van Hemelrijck M
Eur Urol; 2018 Sep; 74(3):261-280. PubMed ID: 29598981
[TBL] [Abstract][Full Text] [Related]
9. PARP inhibitors for homologous recombination-deficient prostate cancer.
Christenson ES; Antonarakis ES
Expert Opin Emerg Drugs; 2018 Jun; 23(2):123-133. PubMed ID: 29595348
[TBL] [Abstract][Full Text] [Related]
10. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
Bhasin S; Brito JP; Cunningham GR; Hayes FJ; Hodis HN; Matsumoto AM; Snyder PJ; Swerdloff RS; Wu FC; Yialamas MA
J Clin Endocrinol Metab; 2018 May; 103(5):1715-1744. PubMed ID: 29562364
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic Plasticity, Bet-Hedging, and Androgen Independence in Prostate Cancer: Role of Non-Genetic Heterogeneity.
Jolly MK; Kulkarni P; Weninger K; Orban J; Levine H
Front Oncol; 2018; 8():50. PubMed ID: 29560343
[TBL] [Abstract][Full Text] [Related]
12. Genetic testing for hereditary prostate cancer: Current status and limitations.
Zhen JT; Syed J; Nguyen KA; Leapman MS; Agarwal N; Brierley K; Llor X; Hofstatter E; Shuch B
Cancer; 2018 Aug; 124(15):3105-3117. PubMed ID: 29669169
[TBL] [Abstract][Full Text] [Related]
13. Resolving the Coffey Paradox: what does the androgen receptor do in normal vs. malignant prostate epithelial cells?
Isaacs JT
Am J Clin Exp Urol; 2018; 6(2):55-61. PubMed ID: 29666833
[TBL] [Abstract][Full Text] [Related]
14. Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide.
Belic J; Graf R; Bauernhofer T; Cherkas Y; Ulz P; Waldispuehl-Geigl J; Perakis S; Gormley M; Patel J; Li W; Geigl JB; Smirnov D; Heitzer E; Gross M; Speicher MR
Int J Cancer; 2018 Sep; 143(5):1236-1248. PubMed ID: 29574703
[TBL] [Abstract][Full Text] [Related]
15. Understanding of multigene test results among males undergoing germline testing for inherited prostate cancer: Implications for genetic counseling.
Giri VN; Obeid E; Hegarty SE; Gross L; Bealin L; Hyatt C; Fang CY; Leader A
Prostate; 2018 Sep; 78(12):879-888. PubMed ID: 29655297
[TBL] [Abstract][Full Text] [Related]
16. A Multi-Institutional Validation of Gleason Score Derived from Tissue Microarray Cores.
Leyh-Bannurah SR; Trudel D; Latour M; Zaffuto E; Grosset AA; Tam C; Ouellet V; Graefen M; Budäus L; Aprikian AG; Lacombe L; Fleshner NE; Gleave ME; Mes-Masson AM; Saad F; Karakiewicz PI
Pathol Oncol Res; 2019 Jul; 25(3):979-986. PubMed ID: 29623528
[TBL] [Abstract][Full Text] [Related]
17. Identification of potential key genes and high-frequency mutant genes in prostate cancer by using RNA-Seq data.
Zhang Z; Wu H; Zhou H; Gu Y; Bai Y; Yu S; An R; Qi J
Oncol Lett; 2018 Apr; 15(4):4550-4556. PubMed ID: 29616087
[TBL] [Abstract][Full Text] [Related]
18. Transition Points for the Routine Integration of Palliative Care in Patients With Advanced Cancer.
Collins A; Sundararajan V; Burchell J; Millar J; McLachlan SA; Krishnasamy M; Le BH; Mileshkin L; Hudson P; Philip J
J Pain Symptom Manage; 2018 Aug; 56(2):185-194. PubMed ID: 29608934
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers in active surveillance.
Loeb S; Tosoian JJ
Transl Androl Urol; 2018 Feb; 7(1):155-159. PubMed ID: 29594029
[TBL] [Abstract][Full Text] [Related]
20. Costs of Cancer Care Across the Disease Continuum.
Kaye DR; Min HS; Herrel LA; Dupree JM; Ellimoottil C; Miller DC
Oncologist; 2018 Jul; 23(7):798-805. PubMed ID: 29567821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
